Heres how to protect your bone health specifically: 1
Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature
Future trials should focus on long-term studies (52+ weeks), comparing retatrutide with semaglutide and tirzepatide, optimising dosing and including cardiovascular, liver, renal and quality-of-life outcomes
Journal Reference : Robert Bozick, Shannon D
Sergey Terushkin, MD, FACS, patients receive ongoing monitoring, dosage adjustments, nutritional guidance, and continued support throughout their weight-loss journey
What medications are used for weight loss
